Alecensa 150 MG capsule UU 240S
Ended Awarded Last action
- Contract number
- SPE2DR26FHDA4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,029
Award facts
- Contract value 100% obligated
- $28,028.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $28,028.92 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 240 units of Alecensa 150 mg capsules. This is a firm fixed-price delivery order with an ultimate completion date of February 10, 2026, and no set-aside designation was used in the award. The contract was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors to supply pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group's PPV-G GEN V prime contract, valued at $499,999,999 and effective through December 31, 2036, authorizes the Defense Logistics Agency to issue delivery orders for branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, and medical consumables. The company has demonstrated substantial contracting activity with the Defense Logistics Agency's Medical Supply Chain division, supplying a diverse portfolio of pharmaceutical products ranging from routine medications to specialized oncology treatments and biologic agents. This delivery order for Alecensa, a branded oncology medication, reflects the company's continued role as a critical supplier within the federal pharmaceutical supply chain supporting military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FHDA4?
SPE2DR26FHDA4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FHDA4 worth?
The government has obligated $28,029 on SPE2DR26FHDA4.
Is contract SPE2DR26FHDA4 an order under another contract?
Yes. SPE2DR26FHDA4 is a delivery order under SPE2DR25D9207, an indefinite delivery contract.
Was contract SPE2DR26FHDA4 competed?
The extent of competition for SPE2DR26FHDA4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award